Khaled A. Shaaban

Prof. Dr. Khaled A. Shaaban

University of Kentucky, Lexington, Kentucky, USA
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2015 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
SESherif Elshahawi
Sherif Elshahawi
Khaled A. ShaabanKhaled A. Shaaban
Khaled A. Shaaban
MKMadan K. Kharel
Madan K. Kharel
JTJon S. Thorson
Jon S. Thorson
A compilation of the rich diversity of bacterial secondary metabolite glycosides.

21 December 2011 in Natural Product Reports
Verified
Journal Article
Closed access
PDF file
MKMadan K. Kharel
Madan K. Kharel
PPPallab Pahari
Pallab Pahari
MSMicah D. Shepherd
Micah D. Shepherd
NTNidhi Tibrewal
Nidhi Tibrewal
SNS. Eric Nybo
S. Eric Nybo
JRJürgen Rohr
Jürgen Rohr
Covering: 1997 to 2010 The angucycline group is the largest group of type II PKS-engineered natural products, rich in biological activities and chemical scaffolds. This stimulated synthetic creativity and biosynthetic inquisitiveness. The synthetic studies used five different strategies, involving Diels-Alder reactions, nucleophilic additions, electrophilic additions, transition-metal mediated cross-couplings and intramolecular cyclizations to generate the angucycline frames. Biosynthetic studies were particularly intriguing when unusual framework rearrangements by post-PKS tailoring oxidoreductases occurred, or when unusual glycosylation reactions were involved in decorating the benz[a]anthracene-derived cores. This review follows our previous reviews, which were published in 1992 and 1997, and covers new angucycline group antibiotics published between 1997 and 2010. However, in contrast to the previous reviews, the main focus of this article is on new synthetic approaches and biosynthetic investigations, most of which were published between 1997 and 2010, but go beyond, e.g. for some biosyntheses all the way back to the 1980s, to provide the necessary context of information.

1 March 2008 in The Journal of Antibiotics
Verified
Journal Article
Closed access
MEMervat Morsy El-Gendy
Mervat Morsy El-Gendy
MSMohamed Shaaban
Mohamed Shaaban
Khaled A. ShaabanKhaled A. Shaaban
Khaled A. Shaaban
AEAhmed Mohamed El-Bondkly
Ahmed Mohamed El-Bondkly
HLHartmut Laatsch
Hartmut Laatsch

18 November 2009 in Journal of Natural Products
Verified
Journal Article
Closed access
UHUsama Hawas
Usama Hawas
MSMohamed Shaaban
Mohamed Shaaban
Khaled A. ShaabanKhaled A. Shaaban
Khaled A. Shaaban
MSMichael Speitling
Michael Speitling
AMArmin Maier
Armin Maier
HLHartmut Laatsch
Hartmut Laatsch

20 October 2009 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Open access
PDF file
LELobna Elleuch
Lobna Elleuch
MSMohamed Shaaban
Mohamed Shaaban
Slim SmaouiSlim Smaoui
Slim Smaoui
LMLotfi Mellouli
Lotfi Mellouli
IKInes Karray-Rebai
Ines Karray-Rebai
HLHartmut Laatsch
Hartmut Laatsch
During our search for Streptomyces spp. as new producers of bioactive secondary metabolites, the ethyl acetate extract of the new terrestrial Streptomyces isolate TN262 delivered eight antimicrobially active compounds. They were identified as 1-acetyl-β-carboline (1), tryptophol (2), cineromycin B (3), 2,3-dihydrocineromycin B (4), cyclo-(tyrosylprolyl) (5), 3-(hydroxyacetyl)-indole (6), brevianamide F (7), and cis-cyclo-(l-prolyl-l-leucyl) (8). Three further metabolites were detected in the unpolar fractions using GC–MS and tentatively assigned as benzophenone (9), N-butyl-benzenesulfonamide (10), and hexanedioic acid-bis-(2-ethylhexyl) ester (11). This last compound is known as plasticizer derivatives, but it has never been described from natural sources. In this article, we describe the identification of the new Streptomyces sp. isolate TN262 using its cultural characteristics, the nucleotide sequence of the corresponding 16S rRNA gene and the phylogenetic analysis, followed by optimization, large-scale fermentation, isolation of the bioactive constituents, and determination of their structures. The biological activity of compounds (2), (3), (4), and those of the unpolar fractions was addressed as well.

6 September 2017 in Frontiers in Microbiology
Verified
Journal Article
Open access
FGFrancielly M. W. R. Gos
Francielly M. W. R. Gos
DSDaiani C. Savi
Daiani C. Savi
Khaled A. ShaabanKhaled A. Shaaban
Khaled A. Shaaban
JTJon S. Thorson
Jon S. Thorson
RARodrigo Aluizio
Rodrigo Aluizio
CGCHIRLEI GLIENKE
CHIRLEI GLIENKE
Endophytic actinomycetes from medicinal plants produce a wide diversity of secondary metabolites (SM). However, to date, the knowledge about endophytes from Brazil remains scarce. Thus, we analyzed the antimicrobial potential of 10 actinomycetes isolated from the medicinal plant Vochysia divergens located in the Pantanal sul-mato-grossense, an unexplored wetland in Brazil. Strains were classified as belonging to the Aeromicrobium, Actinomadura, Microbacterium, Microbispora, Micrococcus, Sphaerisporangium, Streptomyces and Williamsia genera, through morphological and 16S rRNA phylogenetic analyzes. A susceptibility analysis demonstrated that the strains were largely resistant to the antibiotics oxacillin and nalidixic acid. Additionally, different culture media (SG and R5A) and temperatures (28 °C and 36 °C) were evaluated to select the best culture conditions to produce the active SM. All conditions were analyzed for active metabolites, and the best antibacterial activity was observed from metabolites produced with SG medium at 36 °C. The LGMB491 (close related to Aeromicrobium ponti) extract showed the highest activity against methicillin-resistant S. aureus (MRSA), with a MIC of 0.04mg/mL, and it was selected for SM identification. Strain LGMB491 produced 1-acetyl-β-carboline (1), indole-3-carbaldehyde (2), 3-(hydroxyacetyl)-indole (4), brevianamide F (5), and cyclo-(L-Pro-L-Phe) (6) as major compounds with antibacterial activity. In this study, we add to the knowledge about the endophytic community from the medicinal plant V. divergens and report the isolation of rare actinomycetes that produce highly active metabolites.